Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis.
10.1007/s11596-016-1586-7
- Author:
Sheng-Li YANG
1
;
Quan-Guang REN
1
;
Lu WEN
1
;
Jian-Li HU
2
Author Information
1. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
2. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. jl5199@126.com.
- Publication Type:Journal Article
- Keywords:
epidermal growth factor receptor;
hypoxia-inducible factor-1 alpha;
non-small cell lung cancer;
small cell lung cancer;
vascular endothelial growth factor
- MeSH:
Adenocarcinoma;
diagnosis;
genetics;
mortality;
pathology;
Biomarkers, Tumor;
genetics;
metabolism;
Carcinoma, Non-Small-Cell Lung;
diagnosis;
genetics;
mortality;
pathology;
Carcinoma, Squamous Cell;
diagnosis;
genetics;
mortality;
pathology;
Humans;
Hypoxia-Inducible Factor 1, alpha Subunit;
genetics;
metabolism;
Lung Neoplasms;
diagnosis;
genetics;
mortality;
pathology;
Lymphatic Metastasis;
Neoplasm Grading;
Neoplasm Staging;
Odds Ratio;
Prognosis;
Receptor, Epidermal Growth Factor;
genetics;
metabolism;
Survival Analysis;
Vascular Endothelial Growth Factor A;
genetics;
metabolism
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2016;36(3):321-327
- CountryChina
- Language:English
-
Abstract:
Hypoxia-inducible factor-1 alpha (HIF-1α) plays a vital role in the initiation, evaluation and prognosis in lung cancer. The prognostic value of HIF-1α reported in diverse study remains disputable. Accordingly, a meta-analysis was implemented to further understand the prognostic role of HIF-1α in lung cancer. The relationship between HIF-1α and the clinicopathological characteristics and prognosis of lung cancer were investigated by a meta-analysis. PubMed and Embase were searched from their inception to January 2015 for observational studies. Fixed-effects or random-effects meta-analyses were used to calculate odds ratios and 95% confidence intervals of different comparisons. A total of 20 studies met the criteria. The results showed that HIF-1α expression in lung cancer tissues was significantly higher than that in normal lung tissues. Expression of HIF-1α in patients with squamous cell carcinoma was significantly higher than that of patients with adenocarcinomas. Similarly, non-small cell lung cancer (NSCLC) patients had higher HIF-1α expression than small cell lung cancer (SCLC) patients. Moreover, lymph node metastasized tissues had higher HIF-1α expression than non-lymph node metastasized tissues. A high level HIF-1α expression was well correlated with the expression of vascular endothelial growth factor and epidermal growth factor receptor in the NSCLC. Notably, NSCLC or SCLC patients with positive HIF-1α expression in tumor tissues had lower overall survival rate than patients with negative HIF-1α expression. It was suggested that HIF-1α expression may be a prognostic biomarker and a potential therapeutic target for lung cancer.
